Jagsonpal Pharma

30
Sell
  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE048B01035
  • NSEID: JAGSNPHARM
  • BSEID: 507789
INR
186.00
5.75 (3.19%)
BSENSE

Feb 10

BSE+NSE Vol: 61.19 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 28.76% vs -11.83% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 121.40% vs -32.46% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 17.69% vs 97.09% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is 146.45% vs -15.94% in Mar 2024

Compare Profit and Loss Results of Jagsonpal Pharma
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
268.00
542.00
-274.00
-50.55%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
268.00
542.00
-274.00
-50.55%
Expenditure (Ex Depriciation)
Stock Adjustments
-2.00
-20.00
18.00
90.00%
Raw Materials Consumed
98.00
307.00
-209.00
-68.08%
Power & Fuel Cost
0.00
22.00
-22.00
-100.00%
Employee Cost
70.00
57.00
13.00
22.81%
Operating Expenses
0.00
63.00
-63.00
-100.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
24.00
6.00
18.00
300.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
6.00
-6.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
217.00
460.00
-243.00
-52.83%
Operating Profit (PBDIT) excl Other Income
51.00
82.00
-31.00
-37.80%
Other Income
8.00
19.00
-11.00
-57.89%
Operating Profit (PBDIT)
59.00
101.00
-42.00
-41.58%
Interest
0.00
27.00
-27.00
-100.00%
Profit before Depriciation and Tax
58.00
73.00
-15.00
-20.55%
Depreciation
8.00
27.00
-19.00
-70.37%
Profit Before Taxation & Exceptional Items
50.00
46.00
4.00
8.70%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
69.00
46.00
23.00
50.00%
Provision for Tax
14.00
3.00
11.00
366.67%
Profit After Tax
55.00
42.00
13.00
30.95%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
104.00
267.00
-163.00
-61.05%
Profit Available for appropriations
159.00
310.00
-151.00
-48.71%
Appropriations
159.00
310.00
-151.00
-48.71%
Equity Dividend (%)
125%
20%
105.00
Earnings Per Share
8.26
13.29
-5.03
-37.85%
Profit And Loss - Net Sales
Net Sales 268.72 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 28.76% vs -11.83% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 51.07 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 121.40% vs -32.46% in Mar 2024

Profit And Loss - Interest
Interest 0.96 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 17.69% vs 97.09% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax 55.36 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 146.45% vs -15.94% in Mar 2024